Ciurea, Switzerland: no clear benefit of switching to IL-17i rather than another TNFi after failed TNFi in #axial #spondyloarthritis... might even be trend to reduced outcomes in men. Nice example of real-world data challenging largely “evidence-free” dogma #EULAR2019 @RheumNow